The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways

Table 1 Correlations between the expression of STAG3 and clinicopathological features in HCC patients in TCGA dataset

Clinicopathological features	Number, n_max = 384	Low expression, n_max = 187(%)	High expression, n_max = 187(%)	χ2	P value
Age, y
≤ 60	177	87 (23.3)	90 (24.1)	0.069	0.793
> 60	196	99 (26.5)	97 (26.0)	0.069	0.793
Gender
Male	253	124 (33.2)	129 (34.5)	0.680	0.410
Female	121	63 (16.8)	58 (15.5)	0.680	0.410
T stage, n (%)
T1-T2	278	126 (34.0)	152 (41.0)	9.041	0.003**
T3-T4	93	58 (15.6)	35 (9.4)	9.041	0.003**
N stage, n (%)
N0	254	134 (51.9)	120 (46.5)	2.221	0.136
N1	4	1 (0.4)	3 (1.2)	2.221	0.136
M stage, n (%)
M0	268	145 (53.3)	123 (45.2)	2.589	0.108
M1	4	2 (0.7)	2 (0.7)	2.589	0.108
Pathological stage
I–II	260	117 (33.4)	143 (40.9)	8.695	0.003**
III–IV	90	56 (16.0)	34 (9.7)	8.695	0.003**
Tumor status, n (%)
Tumor free	114	88 (24.8)	114 (32.1)	5.288	0.021*
With tumor	153	89 (25.1)	64 (18)

STAG3 stromal antigen 3, HCC hepatocellular carcinoma, TCGA The Cancer Genome Atlas.
*P < 0.05, **P < 0.01.

ISSN: 1471-230X